SPDM - Pesquisas

Clinical Impact, Reactogenicity, and Immunogenicity After the First CoronaVac Dose in Kidney Transplant Recipients

Clinical Impact, Reactogenicity, and Immunogenicity After the First CoronaVac Dose in Kidney Transplant Recipients

In phase-3 trial, inactivated SARS-CoV-2 vaccine (CoronaVac, Sinovac Life-Sciences, Beijing, China) was associated with 71.1% seroconversion at least 14-days after the 2nddose, showing 50.7% efficacy against symptomatic COVID-19 among healthcare workers. Currently this vaccine has been approved for emergency use in 24 countries, including Brazil, where the national vaccination program was launched on 01/Jan/2021 following the age criterion.

Kidney transplant recipients have shown 20-30% COVID-19-associated fatality rates, have been excluded in vaccine trials, and had no early priority for vaccination. Therefore, this single-center, prospective, 12-month follow-up study was designed to assess clinical impact, reactogenicity, and immunogenicity of CoronaVac.

Leia o artigo completo em inglês.

 460
   
   

logo IBROSS
  Filiada ao Instituto Brasileiro das
  Organizações Sociais de Saúde (IBROSS)

Contato | Newsletter

Rua Dr. Diogo de Faria, 1036 | Vila Clementino
Cep: 04037-003 | Telefone: (11) 5549-7032